DIVERSA --- Enzymehersteller für Ethanolproduktion aus Mais + Biomasse + Zellulose ! - 500 Beiträge pro Seite
eröffnet am 15.02.07 13:53:47 von
neuester Beitrag 06.07.07 07:53:10 von
neuester Beitrag 06.07.07 07:53:10 von
Beiträge: 19
ID: 1.112.377
ID: 1.112.377
Aufrufe heute: 0
Gesamt: 2.785
Gesamt: 2.785
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 5553 | |
| heute 11:09 | 3425 | |
| vor 55 Minuten | 2116 | |
| vor 44 Minuten | 2012 | |
| heute 09:10 | 1722 | |
| vor 39 Minuten | 1623 | |
| vor 58 Minuten | 1418 | |
| vor 1 Stunde | 1312 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.954,77 | -0,74 | 220 | |||
| 2. | 3. | 150,90 | -0,44 | 104 | |||
| 3. | 2. | 9,5150 | -1,35 | 93 | |||
| 4. | 4. | 0,1875 | -3,35 | 77 | |||
| 5. | 34. | 0,6250 | -55,36 | 47 | |||
| 6. | 13. | 395,65 | -14,28 | 43 | |||
| 7. | 6. | 0,0211 | -32,59 | 41 | |||
| 8. | 5. | 6,8000 | +0,83 | 40 |
Feedback
ein sehr interessanter Wert, der bisher bei uns zu wenig Beachtung bekommen hat ---dabei ist Diversa eine einfache und gute Anlage um am Ethanolboom zu partizipieren ---ein klassischer "Spaten"-Wert
jmo - aber seht selbst...
http://www.diversa.com
dvsa --- US2550641078
Marktkapitalisierung 364,30 Mio EUR
yahoo finance : BUSINESS SUMMARY
Diversa Corporation engages in the development of specialty enzymes. The company possesses an array of enzymes derived from bio-diverse environments, as well as patented DirectEvolution technologies. It customizes enzymes for manufacturers within the alternative fuel, industrial, and health and nutrition markets. Diversa Corporation?s product portfolio includes enzymes to produce ethanol, cellulosic ethanol, and biodiesel as alternative fuels. In addition, the company markets enzymes for use in industrial process, such as pulp bleaching. Its phytase health and nutrition enzymes are used in animal feed. The company has alliances principally with BASF, Cargill Health and Food Technologies, DuPont Bio-Based Materials, Medarex, Inc., Merck & Co., Inc., Xoma, Ltd, Bayer Animal Health, DSM Pharma Chemicals, The Dow Chemical Company, and Givaudan S.A. It also has a strategic relationship with Syngenta AG. Diversa Corporation was founded in 1994. It was formerly known as Industrial Genome Sciences, Inc. and changed its name to Diversa Corporation in 1997. The company is headquartered in San Diego, California.
ein Blick auf die Allianzen von Diversa :
http://www.diversa.com/Pages/AboutUs/AboutUsAllianceSummary.…
http://www.diversa.com/Pages/AboutUs/AboutUsAllianceSummary.…
hier die Pressemappe als Pdf --lässt sich leichter runterscrollen, als die HP...
http://www.diversa.com/PDFs/Press%20Kit%20v4%20web.pdf
http://www.diversa.com/PDFs/Press%20Kit%20v4%20web.pdf
ALTERNATIVE FUEL MARKET
Trading Spotlight
mal so die letzten meldungen...
Syngenta Medienmitteilungen:
Syngenta und Diversa beschließen neue Partnerschaft zur Erforschung und Entwicklung von Enzymen für Biotreibstoffe
Basel, Schweiz, und San Diego, Kalifornien, USA – 8. Januar 2007
Syngenta und Diversa Corporation haben heute eine neue, auf zehn Jahre angelegte Partnerschaft bekannt gegeben. Die Zusammenarbeit umfasst die Erforschung und Entwicklung einer Reihe neuartiger Enzyme, um vorbehandelte Zellulose-Biomasse wirtschaftlich in gemischte Zucker umzuwandeln – ein entscheidender Schritt zur Herstellung von Biotreibstoffen.
Diese Vereinbarung ermöglicht Diversa unabhängig eigene fermentierungsbasierte Enzymkombinationen zu entwickeln und zu vermarkten. Syngenta erhält das exklusive Zugangsrecht zu diesen Enzymen, um sie für die kosteneffizientere Produktion von Biotreibstoffen zu nutzen.
Die effiziente Umwandlung von Biomasse in Biotreibstoffe erfordert Entwicklungen in drei Bereichen: chemische Vorbereitung der Zellulose-Biomasse (Vorbehandlung), Umwandlung der vorbehandelten Zellulose-Biomasse in fermentierbare Zucker durch die Kombination von Enzymen (Saccharifikation) sowie die Entwicklung innovativer Mikroorganismen zur Fermentierung der Zucker in Ethanol oder andere Treibstoffe (Fermentierung). Die Entwicklung kosteneffizienter Enzymsysteme ist ein zentraler Schritt für eine wirtschaftliche Umwandlung von Biomasse in Biotreibstoffe.
Im Rahmen des neuen Abkommens, das eine frühere Vereinbarung ersetzt, zahlt Syngenta an Diversa in den ersten beiden Jahren 16 Millionen US-Dollar an garantierten Forschungsgeldern. Bei entsprechenden Erfolgen in der Produktentwicklung, erhält Diversa weitere Zahlungen sowie Lizenzgebühren.
«Wir freuen uns über den Abschluss dieses Abkommens mit Diversa», sagte David Jones, Mitglied der Geschäftsleitung von Syngenta. «Diversa verfügt über die besten Kapazitäten, um wirklich innovative Enzyme zu entwickeln. Syngenta verfügt über die Fähigkeit, die Enzyme von Diversa kosteneffizient in Pflanzen zu integrieren. Wir erwarten uns von dieser Partnerschaft hochwertige Produkte für einen Markt mit einem bedeutenden Potenzial.»
«Wir freuen uns, die Zusammenarbeit mit Syngenta, einem weltweit führenden Agribusiness-Unternehmen, neu auszurichten», führte Edward Shonsey, CEO von Diversa aus. «Diese Vereinbarung ermöglicht uns, die Entwicklung im Markt für Biotreibstoffe – durch den ergänzenden Einbau von Enzymen in Pflanzen – weiter voranzutreiben. Zudem hat Diversa durch das Abkommen die Möglichkeit für eine integrierte Vermarktung von Biotreibstoffen, insbesondere aus Zellullose-Biomasse. Wir werden über weitere Entwicklungen unserer Aktivitäten in diesem Gebiet in naher Zukunft informieren.»
Über Syngenta
Syngenta ist ein weltweit führendes Agribusiness-Unternehmen, das sich durch innovative Forschung und Technologie für eine nachhaltige Landwirtschaft einsetzt. Das Unternehmen ist ein Marktführer im Pflanzenschutz und nimmt am Markt für hochwertiges kommerzielles Saatgut Platz drei ein. Der Umsatz 2005 betrug rund USD 8,1 Milliarden. Syngenta beschäftigt mehr als 19’000 Mitarbeiterinnen und Mitarbeiter in über 90 Ländern. Syngenta ist an der Schweizer Börse (SYNN) und an der Börse von New York (SYT) kotiert. Weitere Informationen: www.syngenta.com.
Über Diversa
Die in San Diego ansässige Diversa Corporation (NASDAQ: DVSA) leistet seit 1994 Pionierarbeit in der Entwicklung von High-Performance-Spezialenzymen. Das Unternehmen besitzt weltweit die größte Zahl von Enzymen aus biodiversen Umgebungen sowie patentierter DirectEvolution®-Technologien. Diversa ist auf die individuelle Anpassung von Enzymen für Produzenten in den Marktsegmenten alternative Treibstoffe, Industrie, Gesundheit und Nahrungsmittel spezialisiert. Die Hauptziele sind ein höherer Durchsatz, niedrigere Kosten und eine bessere Umweltbilanz. Weitere Informationen: www.diversa.com
Syngenta Medienmitteilungen:
Syngenta und Diversa beschließen neue Partnerschaft zur Erforschung und Entwicklung von Enzymen für Biotreibstoffe
Basel, Schweiz, und San Diego, Kalifornien, USA – 8. Januar 2007
Syngenta und Diversa Corporation haben heute eine neue, auf zehn Jahre angelegte Partnerschaft bekannt gegeben. Die Zusammenarbeit umfasst die Erforschung und Entwicklung einer Reihe neuartiger Enzyme, um vorbehandelte Zellulose-Biomasse wirtschaftlich in gemischte Zucker umzuwandeln – ein entscheidender Schritt zur Herstellung von Biotreibstoffen.
Diese Vereinbarung ermöglicht Diversa unabhängig eigene fermentierungsbasierte Enzymkombinationen zu entwickeln und zu vermarkten. Syngenta erhält das exklusive Zugangsrecht zu diesen Enzymen, um sie für die kosteneffizientere Produktion von Biotreibstoffen zu nutzen.
Die effiziente Umwandlung von Biomasse in Biotreibstoffe erfordert Entwicklungen in drei Bereichen: chemische Vorbereitung der Zellulose-Biomasse (Vorbehandlung), Umwandlung der vorbehandelten Zellulose-Biomasse in fermentierbare Zucker durch die Kombination von Enzymen (Saccharifikation) sowie die Entwicklung innovativer Mikroorganismen zur Fermentierung der Zucker in Ethanol oder andere Treibstoffe (Fermentierung). Die Entwicklung kosteneffizienter Enzymsysteme ist ein zentraler Schritt für eine wirtschaftliche Umwandlung von Biomasse in Biotreibstoffe.
Im Rahmen des neuen Abkommens, das eine frühere Vereinbarung ersetzt, zahlt Syngenta an Diversa in den ersten beiden Jahren 16 Millionen US-Dollar an garantierten Forschungsgeldern. Bei entsprechenden Erfolgen in der Produktentwicklung, erhält Diversa weitere Zahlungen sowie Lizenzgebühren.
«Wir freuen uns über den Abschluss dieses Abkommens mit Diversa», sagte David Jones, Mitglied der Geschäftsleitung von Syngenta. «Diversa verfügt über die besten Kapazitäten, um wirklich innovative Enzyme zu entwickeln. Syngenta verfügt über die Fähigkeit, die Enzyme von Diversa kosteneffizient in Pflanzen zu integrieren. Wir erwarten uns von dieser Partnerschaft hochwertige Produkte für einen Markt mit einem bedeutenden Potenzial.»
«Wir freuen uns, die Zusammenarbeit mit Syngenta, einem weltweit führenden Agribusiness-Unternehmen, neu auszurichten», führte Edward Shonsey, CEO von Diversa aus. «Diese Vereinbarung ermöglicht uns, die Entwicklung im Markt für Biotreibstoffe – durch den ergänzenden Einbau von Enzymen in Pflanzen – weiter voranzutreiben. Zudem hat Diversa durch das Abkommen die Möglichkeit für eine integrierte Vermarktung von Biotreibstoffen, insbesondere aus Zellullose-Biomasse. Wir werden über weitere Entwicklungen unserer Aktivitäten in diesem Gebiet in naher Zukunft informieren.»
Über Syngenta
Syngenta ist ein weltweit führendes Agribusiness-Unternehmen, das sich durch innovative Forschung und Technologie für eine nachhaltige Landwirtschaft einsetzt. Das Unternehmen ist ein Marktführer im Pflanzenschutz und nimmt am Markt für hochwertiges kommerzielles Saatgut Platz drei ein. Der Umsatz 2005 betrug rund USD 8,1 Milliarden. Syngenta beschäftigt mehr als 19’000 Mitarbeiterinnen und Mitarbeiter in über 90 Ländern. Syngenta ist an der Schweizer Börse (SYNN) und an der Börse von New York (SYT) kotiert. Weitere Informationen: www.syngenta.com.
Über Diversa
Die in San Diego ansässige Diversa Corporation (NASDAQ: DVSA) leistet seit 1994 Pionierarbeit in der Entwicklung von High-Performance-Spezialenzymen. Das Unternehmen besitzt weltweit die größte Zahl von Enzymen aus biodiversen Umgebungen sowie patentierter DirectEvolution®-Technologien. Diversa ist auf die individuelle Anpassung von Enzymen für Produzenten in den Marktsegmenten alternative Treibstoffe, Industrie, Gesundheit und Nahrungsmittel spezialisiert. Die Hauptziele sind ein höherer Durchsatz, niedrigere Kosten und eine bessere Umweltbilanz. Weitere Informationen: www.diversa.com
nit kleckern ...
AP
Consortium Vies for $125M Energy Center
Wednesday January 31, 1:53 pm ET
By Duncan Mansfield, Associated Press Writer
Oak Ridge Consortium Vies for $125 Million Alternative Fuel Center
KNOXVILLE, Tenn. (AP) -- The Oak Ridge National Laboratory is proposing with several academic and industrial partners to host a $125 million bio-energy center that will concentrate on turning switchgrass and poplar trees into a competitive source of ethanol in five years.
"They have figured out that we cannot grow enough corn in North America to do what we need to do ... so they are looking at lots of different types of plants and trees to make ethanol," lab spokesman Billy Stair said.
The Department of Energy facility is teaming with the University of Tennessee, the University of Georgia, Georgia Institute of Technology, Dartmouth College, the National Renewable Energy Laboratory in Colorado and the Samuel Roberts Noble Foundation in Oklahoma.
Along with three industrial partners, the Oak Ridge lab is applying for a five-year, $25-million-a-year grant from DOE's Office of Science. Two bio-centers will be funded, and several other institutions, including Purdue University, University of California-Berkeley and the Massachusetts Institute of Technology, are expected to be in the running.
Oak Ridge is proposing to house the center at its new Joint Institute for Biological Sciences building, a state-funded research center due to open in August, about the same time the Office of Science will announce its grant recipients.
The lab's proposal anticipates benefiting from Oak Ridge's supercomputing center and a proposed 5 million-gallon-per-year, switchgrass-to-ethanol demonstration project in Tennessee that could open in as little as two years.
Tennessee Gov. Phil Bredesen on Wednesday planned to announce his alternative fuel proposals for his 2007-2008 budget.
"You have got to do three things to make it all come together," Stair said. "You've got to be able to grow the commodity in substantial quantity. You have to break down the commodity into celluosic sugars so you can make ethanol from it. (And) you have to figure out how to make it (ethanol) in substantial quantities."
Stair said Oak Ridge's proposal will "include all three elements and we hope, of course, that will make our proposal unique."
Reinhold Mann, the lab's associate director heading biological and environmental sciences, said researchers have a good understanding of switchgrass -- which can grow in many places without much effort -- and poplar -- which grows very fast.
But further work needs to be done on breaking down the plants more efficiently to convert their sugars into fuel. The goal is to replace chemical treatments with microbes that can deliver a "single-step conversion of biomass to biofuels," Mann said.
Currently processing poplar and switchgrass into ethanol costs around $2 to $2.80 a gallon, Mann said. "We need to bring that down by about half to get in the realm of where it is competitive not just with gasoline but also ethanol derived from corn."
Oak Ridge's industrial partners are ArborGen LLC of Summerville, S.C., which is involved in genetics research for the forestry industry; San Diego-based Diversa Corp., which develops high-performance specialty enzymes, and Mascoma Corp., a Cambridge, Mass.-based firm involved ethanol research.
AP
Consortium Vies for $125M Energy Center
Wednesday January 31, 1:53 pm ET
By Duncan Mansfield, Associated Press Writer
Oak Ridge Consortium Vies for $125 Million Alternative Fuel Center
KNOXVILLE, Tenn. (AP) -- The Oak Ridge National Laboratory is proposing with several academic and industrial partners to host a $125 million bio-energy center that will concentrate on turning switchgrass and poplar trees into a competitive source of ethanol in five years.
"They have figured out that we cannot grow enough corn in North America to do what we need to do ... so they are looking at lots of different types of plants and trees to make ethanol," lab spokesman Billy Stair said.
The Department of Energy facility is teaming with the University of Tennessee, the University of Georgia, Georgia Institute of Technology, Dartmouth College, the National Renewable Energy Laboratory in Colorado and the Samuel Roberts Noble Foundation in Oklahoma.
Along with three industrial partners, the Oak Ridge lab is applying for a five-year, $25-million-a-year grant from DOE's Office of Science. Two bio-centers will be funded, and several other institutions, including Purdue University, University of California-Berkeley and the Massachusetts Institute of Technology, are expected to be in the running.
Oak Ridge is proposing to house the center at its new Joint Institute for Biological Sciences building, a state-funded research center due to open in August, about the same time the Office of Science will announce its grant recipients.
The lab's proposal anticipates benefiting from Oak Ridge's supercomputing center and a proposed 5 million-gallon-per-year, switchgrass-to-ethanol demonstration project in Tennessee that could open in as little as two years.
Tennessee Gov. Phil Bredesen on Wednesday planned to announce his alternative fuel proposals for his 2007-2008 budget.
"You have got to do three things to make it all come together," Stair said. "You've got to be able to grow the commodity in substantial quantity. You have to break down the commodity into celluosic sugars so you can make ethanol from it. (And) you have to figure out how to make it (ethanol) in substantial quantities."
Stair said Oak Ridge's proposal will "include all three elements and we hope, of course, that will make our proposal unique."
Reinhold Mann, the lab's associate director heading biological and environmental sciences, said researchers have a good understanding of switchgrass -- which can grow in many places without much effort -- and poplar -- which grows very fast.
But further work needs to be done on breaking down the plants more efficiently to convert their sugars into fuel. The goal is to replace chemical treatments with microbes that can deliver a "single-step conversion of biomass to biofuels," Mann said.
Currently processing poplar and switchgrass into ethanol costs around $2 to $2.80 a gallon, Mann said. "We need to bring that down by about half to get in the realm of where it is competitive not just with gasoline but also ethanol derived from corn."
Oak Ridge's industrial partners are ArborGen LLC of Summerville, S.C., which is involved in genetics research for the forestry industry; San Diego-based Diversa Corp., which develops high-performance specialty enzymes, and Mascoma Corp., a Cambridge, Mass.-based firm involved ethanol research.
die empfehlung ist mir zwar ein wenig zu euphorisch, aber ich will sie natürlich niemandem vorenthalten ...
06.02.2007 11:21:21
PERFORMAXX-ANLEGERBRIEF-KOLUMNE: Diversa - Spekulation auf Turnaround
MÜNCHEN - Auf den ersten, fundamentalen Blick sieht die Aktie von Diversa Corp.
(US-Kürzel DVSA) weniger attraktiv aus. Von den aktuellen Cash-Reserven von ca.
60 Mio. US-$ verbrennt das Unternehmen um die 20 Mio. US-$ pro Jahr. Doch weckt
das eigentliche Forschungsgebiet im Enzymbereich zur Beschleunigung von
Spaltungsprozessen Phantasie für diverse Anwendungsgebiete. Alles nur Fiktion
und Wunschdenken oder schon bald Wirklichkeit? Völlig unabhängig davon spricht
derzeit bei genauer charttechnischer Betrachtung Einiges eher für steigende
Diversa-Kurse – und das nach langer Zeit!
DAS ENDE DES ABWÄRTSTRENDS
Nach dem Erreichen des Kurshochs bei 169,19 US-$, gleich nach der Emission
Anfang 2000, ging der Aktienkurs von Diversa in einen steilen Abwärtstrend über
und bildete erst im Frühjahr 2005 bei 5 US-$ einen nachhaltigen Boden aus. Dort
konsolidierte das Papier einige Monate, bevor es Anfang 2006 mit einer
impulsiven Bewegung seinen Abwärtstrend und die laufende Bodenbewegung nach oben
verlassen konnte, was als zweites positives Zeichen für einen Turn-around
gewertet werden kann. Innerhalb weniger Wochen verteuerte sich die Aktie auf
fast 12 US-$, ehe eine Konsolidierung unterhalb jener Marke einsetzte und im
Gesamtkontext mit der Bodenbildung eine Untertassen-Formation ausbildete.
AUSBRUCH NOCH ABWARTEN
Diese Art von Umkehrformation tritt relativ selten auf. Die
Untertassen-Formation besteht aus zwei Bestandteilen: Zum einen aus der oberen
Plattform, welche bei Diversa als Widerstandslinie bei 12 US-$ zu erkennen ist,
und zum anderen aus der so genannten Untertasse, die im Falle der Biotech-Aktie
die Bodenbildung bei 5 US-$ widerspiegelt. Sollte die Widerstandsplattform bei
12 US-$ nun in den nächsten Wochen überwunden werden, könnte charttechnisch eine
deutliche Kurserholung folgen. Für die Untertassen-Formation an sich gibt es
keine präzise Kursziel-Regel, da die Dynamik nach den monatelangen
Korrekturbewegungen schlecht absehbar ist. Zur Bestimmung eines minimalen
Kursziels wird deshalb gerne eine allgemeine Regel verwendet, welche die
Differenz zwischen Hoch- und Tiefpunkt der Formation zum Ausbruchspunkt hinzu
addiert. Im Falle von Diversa ergäbe sich ein lineares Kursziel von knapp
20 US-$, unter logarithmischer Berechnung sogar ein Ziel von 30 US-$.
STRATEGIE
Derzeit sieht es bei Diversa ganz nach einem vollzogenen Turnaround aus. Ein
neuerliches Kaufsignal würde aber erst mit dem Ausbruch über den Widerstand von
12 US-$ ausgelöst. Technisch wäre damit die Fortsetzung des Aufwärtstrends
bestätigt und die oben genannten Zielmarken bei 20 respektive 30 US-$ sollten
entsprechend angesteuert werden. Der Biotech-Wert ist jedoch sehr mit Vorsicht
zu genießen, denn die Branche ist von Haus aus äußerst volatil. Spekulative
Investoren sind daher mit Stopps um die technisch relevante Marke von 9,50 US-$
gut beraten.
Für die Inhalte der Kolumne ist allein die Redaktion des
Performaxx-Anlegerbriefs verantwortlich. Die Kolumne erscheint jeden Dienstag in
technischer Zusammenarbeit mit dpa-AFX.
Quelle:dpa-AFX
06.02.2007 11:21:21
PERFORMAXX-ANLEGERBRIEF-KOLUMNE: Diversa - Spekulation auf Turnaround
MÜNCHEN - Auf den ersten, fundamentalen Blick sieht die Aktie von Diversa Corp.
(US-Kürzel DVSA) weniger attraktiv aus. Von den aktuellen Cash-Reserven von ca.
60 Mio. US-$ verbrennt das Unternehmen um die 20 Mio. US-$ pro Jahr. Doch weckt
das eigentliche Forschungsgebiet im Enzymbereich zur Beschleunigung von
Spaltungsprozessen Phantasie für diverse Anwendungsgebiete. Alles nur Fiktion
und Wunschdenken oder schon bald Wirklichkeit? Völlig unabhängig davon spricht
derzeit bei genauer charttechnischer Betrachtung Einiges eher für steigende
Diversa-Kurse – und das nach langer Zeit!
DAS ENDE DES ABWÄRTSTRENDS
Nach dem Erreichen des Kurshochs bei 169,19 US-$, gleich nach der Emission
Anfang 2000, ging der Aktienkurs von Diversa in einen steilen Abwärtstrend über
und bildete erst im Frühjahr 2005 bei 5 US-$ einen nachhaltigen Boden aus. Dort
konsolidierte das Papier einige Monate, bevor es Anfang 2006 mit einer
impulsiven Bewegung seinen Abwärtstrend und die laufende Bodenbewegung nach oben
verlassen konnte, was als zweites positives Zeichen für einen Turn-around
gewertet werden kann. Innerhalb weniger Wochen verteuerte sich die Aktie auf
fast 12 US-$, ehe eine Konsolidierung unterhalb jener Marke einsetzte und im
Gesamtkontext mit der Bodenbildung eine Untertassen-Formation ausbildete.
AUSBRUCH NOCH ABWARTEN
Diese Art von Umkehrformation tritt relativ selten auf. Die
Untertassen-Formation besteht aus zwei Bestandteilen: Zum einen aus der oberen
Plattform, welche bei Diversa als Widerstandslinie bei 12 US-$ zu erkennen ist,
und zum anderen aus der so genannten Untertasse, die im Falle der Biotech-Aktie
die Bodenbildung bei 5 US-$ widerspiegelt. Sollte die Widerstandsplattform bei
12 US-$ nun in den nächsten Wochen überwunden werden, könnte charttechnisch eine
deutliche Kurserholung folgen. Für die Untertassen-Formation an sich gibt es
keine präzise Kursziel-Regel, da die Dynamik nach den monatelangen
Korrekturbewegungen schlecht absehbar ist. Zur Bestimmung eines minimalen
Kursziels wird deshalb gerne eine allgemeine Regel verwendet, welche die
Differenz zwischen Hoch- und Tiefpunkt der Formation zum Ausbruchspunkt hinzu
addiert. Im Falle von Diversa ergäbe sich ein lineares Kursziel von knapp
20 US-$, unter logarithmischer Berechnung sogar ein Ziel von 30 US-$.
STRATEGIE
Derzeit sieht es bei Diversa ganz nach einem vollzogenen Turnaround aus. Ein
neuerliches Kaufsignal würde aber erst mit dem Ausbruch über den Widerstand von
12 US-$ ausgelöst. Technisch wäre damit die Fortsetzung des Aufwärtstrends
bestätigt und die oben genannten Zielmarken bei 20 respektive 30 US-$ sollten
entsprechend angesteuert werden. Der Biotech-Wert ist jedoch sehr mit Vorsicht
zu genießen, denn die Branche ist von Haus aus äußerst volatil. Spekulative
Investoren sind daher mit Stopps um die technisch relevante Marke von 9,50 US-$
gut beraten.
Für die Inhalte der Kolumne ist allein die Redaktion des
Performaxx-Anlegerbriefs verantwortlich. Die Kolumne erscheint jeden Dienstag in
technischer Zusammenarbeit mit dpa-AFX.
Quelle:dpa-AFX
die letzte Meldung, die der Markt bisher m.E.. so gut wie ignoriert hat...
Monday February 12, 1:21 pm ET
Diversa Agrees to Buy Cellulosic Ethanol Maker Celunol for $154.7 Million in Stock, Plus Debt
SAN DIEGO (AP) -- Biotechnology company Diversa Corp. saw its shares spring to a new 52-week high on news that it will acquire Celunol Corp., a private company that is developing technology to make ethanol from sugarcane waste.
Diversa Corp., which develops enzymes and biological compounds, agreed Monday to acquire Celunol for $154.7 million in stock, plus debt financing.
Celunol is working to commercialize cellulosic ethanol, an emerging technology in which ethanol is wrung from biomass containing cellulose, such as switchgrass or wood. Production of cellulosic ethanol differs from traditional ethanol production in that the manufacturing process uses enzymes to break down matter into ethanol, rather than using natural gas to provide energy for the process.
It's a technology that is considered cleaner than traditional ethanol because it produces fewer greenhouse gases -- but cellulosic ethanol has yet to be commercialized on any large scale in the U.S. due in part to cost issues.
Diversa believes that its acquisition of Celunol will take it substantially closer to that end.
Cambridge, Mass.-based Celunol recently started up its first cellulosic ethanol pilot facility in Jennings, La. By the end of 2007, the company expects to complete a demonstration-scale plant with capacity to produce 1.4 million gallon of cellulosic ethanol annually, made from sugarcane bagasse and specially bred energy cane.
Sugarcane bagasse is the woody material left after squeezing all the sugar out of the cane.
Its first commercial-scale cellulosic ethanol plants are expected to be operational in 2009.
Under the terms of the acquisition, Diversa will issue 15 million shares to acquire the outstanding equity of Celunol. Diversa will also provide the company with up to $20 million in debt financing to fund its operations through the close of the deal.
Canaccord Adams analyst Avinash Kant said he believes the purchase is a "move in the right direction."
"The holy grail of this technology is ethanol from biomass," Kant said in a telephone interview.
The idea is that the combined company would ultimately be able to produce ethanol from a variety of sources, based on Diversa's array of enzymes that could be used to break down diverse raw materials into ethanol, he said.
Kant began rates the stock a "Buy" with a 12-month price target of $13.
Shares of Diversa rose 49 cents, or 4.8 percent, to $10.80 in afternoon trading on the Nasdaq. The stock swung to a fresh 52-week peak of $12.44 in earlier trading. Previously, shares had traded between $6 and $11.98 over the past year.
Diversa stockholders will own about 76 percent of the combined company, and Celunol stockholders will hold the remaining 24 percent. The deal is subject to stockholder and regulatory approval.
Celunol President and Chief Executive Carlos A. Riva, 53, becomes CEO of the combined company and a director. Celunol's Chief Financial Officer John A. McCarthy Jr., 48, will take on the same role in the combined entity. Another two Celunol directors, apart from Riva, will become Diversa board members.
The Celunol executives will replace Diversa CEO Edward T. Shonsey and current CFO Anthony Altig, according to a spokeswoman.
UBS Investment Bank acted as financial adviser and Cooley Godward Kronish LLP acted as legal counsel to Diversa.
The transaction is expected to close by the end of the second quarter this year.
Diversa shares closed Friday at $10.31 on the Nasdaq. Its shares have traded between $6 and $11.98 over the past year.
Monday February 12, 1:21 pm ET
Diversa Agrees to Buy Cellulosic Ethanol Maker Celunol for $154.7 Million in Stock, Plus Debt
SAN DIEGO (AP) -- Biotechnology company Diversa Corp. saw its shares spring to a new 52-week high on news that it will acquire Celunol Corp., a private company that is developing technology to make ethanol from sugarcane waste.
Diversa Corp., which develops enzymes and biological compounds, agreed Monday to acquire Celunol for $154.7 million in stock, plus debt financing.
Celunol is working to commercialize cellulosic ethanol, an emerging technology in which ethanol is wrung from biomass containing cellulose, such as switchgrass or wood. Production of cellulosic ethanol differs from traditional ethanol production in that the manufacturing process uses enzymes to break down matter into ethanol, rather than using natural gas to provide energy for the process.
It's a technology that is considered cleaner than traditional ethanol because it produces fewer greenhouse gases -- but cellulosic ethanol has yet to be commercialized on any large scale in the U.S. due in part to cost issues.
Diversa believes that its acquisition of Celunol will take it substantially closer to that end.
Cambridge, Mass.-based Celunol recently started up its first cellulosic ethanol pilot facility in Jennings, La. By the end of 2007, the company expects to complete a demonstration-scale plant with capacity to produce 1.4 million gallon of cellulosic ethanol annually, made from sugarcane bagasse and specially bred energy cane.
Sugarcane bagasse is the woody material left after squeezing all the sugar out of the cane.
Its first commercial-scale cellulosic ethanol plants are expected to be operational in 2009.
Under the terms of the acquisition, Diversa will issue 15 million shares to acquire the outstanding equity of Celunol. Diversa will also provide the company with up to $20 million in debt financing to fund its operations through the close of the deal.
Canaccord Adams analyst Avinash Kant said he believes the purchase is a "move in the right direction."
"The holy grail of this technology is ethanol from biomass," Kant said in a telephone interview.
The idea is that the combined company would ultimately be able to produce ethanol from a variety of sources, based on Diversa's array of enzymes that could be used to break down diverse raw materials into ethanol, he said.
Kant began rates the stock a "Buy" with a 12-month price target of $13.
Shares of Diversa rose 49 cents, or 4.8 percent, to $10.80 in afternoon trading on the Nasdaq. The stock swung to a fresh 52-week peak of $12.44 in earlier trading. Previously, shares had traded between $6 and $11.98 over the past year.
Diversa stockholders will own about 76 percent of the combined company, and Celunol stockholders will hold the remaining 24 percent. The deal is subject to stockholder and regulatory approval.
Celunol President and Chief Executive Carlos A. Riva, 53, becomes CEO of the combined company and a director. Celunol's Chief Financial Officer John A. McCarthy Jr., 48, will take on the same role in the combined entity. Another two Celunol directors, apart from Riva, will become Diversa board members.
The Celunol executives will replace Diversa CEO Edward T. Shonsey and current CFO Anthony Altig, according to a spokeswoman.
UBS Investment Bank acted as financial adviser and Cooley Godward Kronish LLP acted as legal counsel to Diversa.
The transaction is expected to close by the end of the second quarter this year.
Diversa shares closed Friday at $10.31 on the Nasdaq. Its shares have traded between $6 and $11.98 over the past year.
der Chart sieht dazu auch so aus, als würde er bald mal einen kleinen Ausbruch wagen...
auch wenn das Unternehmen erst wohl 2008/09 die Gewinnschwelle nachhaltig erreichen dürfte ---finde ich das Diversa ein ausgezeichnetes Langfristplay auf Ethanol werden könnte.
Gruß Pokerdog
& Kölle Alaaf !
auch wenn das Unternehmen erst wohl 2008/09 die Gewinnschwelle nachhaltig erreichen dürfte ---finde ich das Diversa ein ausgezeichnetes Langfristplay auf Ethanol werden könnte.
Gruß Pokerdog
& Kölle Alaaf !
Antwort auf Beitrag Nr.: 27.723.152 von PokerDog am 15.02.07 14:31:19ganz Unrecht hatte ich ja nicht mit Behauptung, dass der Kurs ausbrechen wird--nur leider falsche Richtung...
viele in USA wollen den merger negativ sehen---dabei entsteht hier gerade ein Ethanolweltkonzern!!!
m.E. wird die Verbindung Diversa & Celunol gepaart mit Technik von Sunopta eine Hauptrolle in dem Ethanolmarkt der kommenden Jahre spielen-neben so Unternehmen wie Abengoa und ADM.
Durch den Merger scheint auch gleich Verasun zum heißen Übernahmekandidaten geworden zu sein - wundern würde mich dies nicht, bei einem 08er KGV von 14(peix ist immer noch tiefrot!)
auf jeden fall hab ich am freitag nochmal zu 6,50 nachfassen können---hoffe den Tiefpunkt damit erwischt zu haben...
viele in USA wollen den merger negativ sehen---dabei entsteht hier gerade ein Ethanolweltkonzern!!!
m.E. wird die Verbindung Diversa & Celunol gepaart mit Technik von Sunopta eine Hauptrolle in dem Ethanolmarkt der kommenden Jahre spielen-neben so Unternehmen wie Abengoa und ADM.
Durch den Merger scheint auch gleich Verasun zum heißen Übernahmekandidaten geworden zu sein - wundern würde mich dies nicht, bei einem 08er KGV von 14(peix ist immer noch tiefrot!)
auf jeden fall hab ich am freitag nochmal zu 6,50 nachfassen können---hoffe den Tiefpunkt damit erwischt zu haben...
einsteigen leute!!!
Antwort auf Beitrag Nr.: 28.453.188 von scopus am 23.03.07 14:59:53hab dann auch mal nen batzen stocks um € 5,91 gekauft. ich denke längerfristig geht kein weg dran vorbei das dieses dingens hier richtung nordost geht... ich bin immer recht vorsichtig mit prognosen, aber wenn die jungens in der firma nicht irgendeine interne scheiße bauen, dann rechne ich mit verdopplung zum jahresende, sprich 12 - 15 US$!!!
Hallo,
habe mich heute zu 4,65Euro beteiligt!
Na dann schauen wir mal was die nächsten 24Monate so bringen!?
Der Sektor "Biomasse" wurde in den letzten Jahren bei den Anlegern nicht so recht wahrgenommen. Dabei steckt dort das meiste Potential. Habe neulich einen Bericht gesehen, in dem die Rede von einer möglichen Wirkungsgradsteigerung von ca. 100% die Rede war, allerdings nur in Verbindung mit den richtigen Enzymen!
habe mich heute zu 4,65Euro beteiligt!
Na dann schauen wir mal was die nächsten 24Monate so bringen!?
Der Sektor "Biomasse" wurde in den letzten Jahren bei den Anlegern nicht so recht wahrgenommen. Dabei steckt dort das meiste Potential. Habe neulich einen Bericht gesehen, in dem die Rede von einer möglichen Wirkungsgradsteigerung von ca. 100% die Rede war, allerdings nur in Verbindung mit den richtigen Enzymen!
...ach ja: In dem Bericht wurde in diesem Zusammenhang auch von BASF geredet!
Da hätte ich eine passende Meldung aus dem Mai:
http://biz.yahoo.com/prnews/070517/aqth069.html?.v=6
Da hätte ich eine passende Meldung aus dem Mai:
http://biz.yahoo.com/prnews/070517/aqth069.html?.v=6
Hallo,
habe Diversa schon einige Zeit auf meiner Watchlist und wollte mir jetzt welche zulegen, da hab folgende Nachricht gefunden.
Mein Englich ist nicht so gut - kann mir jemand sagen was da sinngemäss drinsteht.
Haben sich Diversa und Verenium zusammengetan oder wurde Diversa übernommen?
Was ist mit den Diversa-Shares?
Ist das ganze jetzt gut oder schlecht?
Für eine Antwort wäre ich dankbar.
emsa
Focus on Cellulosic Biofuel Development and Commercialization of
Diversified Industrial Enzyme Portfolio
Company to Trade on NASDAQ Global Market under the Symbol 'VRNM'
CAMBRIDGE, Mass. and SAN DIEGO, June 20 /PRNewswire-FirstCall/ --
Diversa Corporation (Nasdaq: DVSA) and Celunol Corp. announced today that
they have completed their previously-announced merger transaction to create
a new leader in the global biofuels industry. The combined company, which
has been renamed Verenium Corporation, possesses a growing portfolio of
specialty enzyme products and unique technical and operational capabilities
designed to enable the production of low-cost, biomass-derived sugars for a
multitude of major industrial applications. The most significant near-term
commercial opportunity for Verenium will be the large-scale commercial
production of cellulosic ethanol derived from multiple biomass feedstocks.
In connection with the corporate name change, the Company has also changed
its NASDAQ ticker symbol from "DVSA" to "VRNM" and will begin trading under
the new ticker symbol effective June 21, 2007.
Stockholders of both companies approved the merger and merger-related
proposals earlier today, and all regulatory approvals and closing
conditions have been satisfied.
"We are pleased that our respective shareholders have approved our
merger and believe their support reinforces our belief in the compelling
investment proposition afforded by this transaction," said Carlos A. Riva,
President and Chief Executive Officer of Verenium. "After several months of
diligent integration planning between the two companies, we are excited to
become a single organization and are confident that the transaction
represents a unique opportunity for our partners, employees, and
shareholders."
"Verenium is now positioned to be a vertically-integrated leader in the
rapidly-evolving worldwide biofuels industry through the unique combination
of assets, technologies, and personnel resulting from this merger. We
believe that commercial success in this industry requires broad R&D
capabilities and asset development expertise, which we have now brought
together within one, highly-focused company, Verenium Corporation."
Verenium begins operations with numerous unique attributes, including:
-- Fully-integrated, end-to-end capabilities in pre-treatment, novel
enzyme development, fermentation, engineering, and project development;
-- One of the only operational cellulosic ethanol pilot plants in the
United States;
-- A 1.4 million gallon-per-year demonstration-scale facility, currently
under construction, to produce cellulosic ethanol from sugarcane
bagasse and specially-bred energy cane;
-- A diverse and growing portfolio of commercialized industrial enzyme
products; and
-- Over 300 issued or in-licensed patents for its technologies and
processes, as well as over 450 pending patents.
Verenium will be structured and managed as three distinct, but
interdependent, organizational units: Specialty Enzymes Business Unit,
Biofuels Business Unit, and Research and Development. The Specialty Enzymes
Business Unit currently generates commercial revenue from multiple sources,
including industrial enzyme product sales, technology licenses, strategic
partnerships, and government grants. The Biofuels Business Unit will be
primary focused on the commercial-scale production and sale of cellulosic
ethanol from company-managed production facilities throughout the US, as
well as strategic partnerships and related revenue arrangements around the
world. The Research and Development organization's primary goal will be to
support both Verenium Business Units, as well as various existing strategic
collaborative partners. As of March 31, 2007, the Company had cash,
cash-equivalents, and short-term investments on hand of approximately
$125.5 million, which, together with approximately $20 million received in
early April from the exercise of an over-allotment option related to the
recent convertible notes offering, it believes to be sufficient to fund
operations through at least 2008.
Verenium's Board of Directors will initially consist of nine members,
six from Diversa and three from Celunol, including Mr. Riva. The
non-employee Board members are: Dr. James Cavanaugh, who will serve as
Chairman of the Board of Directors; Peter Johnson; Fernand Kaufmann, Ph.D.;
Mark Leschly; Melvin Simon, Ph.D.; Cheryl Wenzinger; Joshua Ruch; and
Michael Zak.
The Company's executive management team is being led by Carlos A. Riva,
President, Chief Executive Officer, and Director, and John A. McCarthy,
Jr., Executive Vice President and Chief Financial Officer.
Verenium will be headquartered in Cambridge, Massachusetts and have
research and operations facilities in San Diego, California; Jennings,
Louisiana; and Gainesville, Florida. Due to the complementary nature of the
two companies and the level of development activities being pursued, the
company anticipates increasing its staff in Cambridge and Jennings, as well
as building additional staff over time in San Diego to support the growth
of the enzyme business and research and development efforts of the Company.
In connection with the merger, Diversa will issue 15 million shares of
common stock in exchange for all outstanding equity securities of Celunol,
which includes shares issuable under Celunol options and warrants that will
be assumed by the Company. As a result of the merger, former Celunol
security holders will own approximately 24 percent of the Company, while
Diversa shareholders will own approximately 76 percent. Immediately
following the merger, the Company will have approximately 63 million shares
outstanding.
About Verenium
Cambridge-based Verenium Corporation is a leader in the development and
commercialization of cellulosic ethanol, an environmentally-friendly and
renewable transportation fuel, as well as high-performance specialty
enzymes for applications within the biofuels, industrial, and health and
nutrition markets. The Company possesses integrated, end-to-end
capabilities in pre- treatment, novel enzyme development, fermentation,
engineering, and project development and is moving rapidly to commercialize
its proprietary technology for the production of ethanol from a wide array
of feedstocks, including sugarcane bagasse, dedicated energy crops,
agricultural waste, and wood products. In addition to the vast potential
for biofuels, a multitude of large-scale industrial opportunities exist for
the Company for products derived from the production of low-cost,
biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to
create a broad range of specialty products to meet high-value commercial
needs. Verenium's world class R&D organization is renowned for its
capabilities in the rapid screening, identification, and expression of
enzymes-proteins that act as the catalysts of biochemical reactions.
Verenium recently completed a significant upgrade of one of the
nation's first operational cellulosic ethanol pilot facilities located in
Jennings, Louisiana and expects to achieve mechanical completion of a 1.4
million gallon-per-year, demonstration-scale facility to produce cellulosic
ethanol by the end of 2007. In addition, the Company's process technology
has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co.,
LTD and has been incorporated into BioEthanol Japan's 1.4 million
liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's
first commercial-scale plant to produce cellulosic ethanol from wood
construction waste. For more information on Verenium, visit
http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include statements related to the Company's competitive advantages and
position, technical, operations, production and personnel capabilities,
commercial opportunities, prospects for technical and commercial
development and success, plans for expanding its cellulosic ethanol
business, including by managing production facilities throughout the U.S.
and through strategic partnerships and other arrangements elsewhere, and
other growth, and the sufficiency of its cash equivalents to fund its
operations through 2008. Such statements are only predictions, and actual
events or results may differ materially from those projected in such
forward-looking statements. Factors that could cause or contribute to
differences include, but are not limited to, the risk that the Company may
not be able to successfully integrate its businesses or achieve synergies
in a timely manner or to the extent anticipated, the risk that the
marketplace for the Company's products and product candidates may change or
be impacted by competition, supply issues or marketplace trends, the risk
that technical, regulatory or manufacturing issues, new data or
intellectual property disputes may affect the Company's commercial and/or
development programs or that the Company may encounter other difficulties
in developing its products, product candidates, and/or processes or in
gaining approval or market acceptance of new products, processes, and/or
technologies and risks and other uncertainties more fully described in the
Company's (formerly Diversa's) filings with the Securities and Exchange
Commission, including, but not limited to, the Company's (formerly
Diversa's) quarterly report on Form 10-Q for the quarter ended March 31,
2007. These forward-looking statements speak only as of the date hereof.
The Company expressly disclaims any intent or obligation to update these
forward-looking statements.
habe Diversa schon einige Zeit auf meiner Watchlist und wollte mir jetzt welche zulegen, da hab folgende Nachricht gefunden.
Mein Englich ist nicht so gut - kann mir jemand sagen was da sinngemäss drinsteht.
Haben sich Diversa und Verenium zusammengetan oder wurde Diversa übernommen?
Was ist mit den Diversa-Shares?
Ist das ganze jetzt gut oder schlecht?
Für eine Antwort wäre ich dankbar.
emsa
Focus on Cellulosic Biofuel Development and Commercialization of
Diversified Industrial Enzyme Portfolio
Company to Trade on NASDAQ Global Market under the Symbol 'VRNM'
CAMBRIDGE, Mass. and SAN DIEGO, June 20 /PRNewswire-FirstCall/ --
Diversa Corporation (Nasdaq: DVSA) and Celunol Corp. announced today that
they have completed their previously-announced merger transaction to create
a new leader in the global biofuels industry. The combined company, which
has been renamed Verenium Corporation, possesses a growing portfolio of
specialty enzyme products and unique technical and operational capabilities
designed to enable the production of low-cost, biomass-derived sugars for a
multitude of major industrial applications. The most significant near-term
commercial opportunity for Verenium will be the large-scale commercial
production of cellulosic ethanol derived from multiple biomass feedstocks.
In connection with the corporate name change, the Company has also changed
its NASDAQ ticker symbol from "DVSA" to "VRNM" and will begin trading under
the new ticker symbol effective June 21, 2007.
Stockholders of both companies approved the merger and merger-related
proposals earlier today, and all regulatory approvals and closing
conditions have been satisfied.
"We are pleased that our respective shareholders have approved our
merger and believe their support reinforces our belief in the compelling
investment proposition afforded by this transaction," said Carlos A. Riva,
President and Chief Executive Officer of Verenium. "After several months of
diligent integration planning between the two companies, we are excited to
become a single organization and are confident that the transaction
represents a unique opportunity for our partners, employees, and
shareholders."
"Verenium is now positioned to be a vertically-integrated leader in the
rapidly-evolving worldwide biofuels industry through the unique combination
of assets, technologies, and personnel resulting from this merger. We
believe that commercial success in this industry requires broad R&D
capabilities and asset development expertise, which we have now brought
together within one, highly-focused company, Verenium Corporation."
Verenium begins operations with numerous unique attributes, including:
-- Fully-integrated, end-to-end capabilities in pre-treatment, novel
enzyme development, fermentation, engineering, and project development;
-- One of the only operational cellulosic ethanol pilot plants in the
United States;
-- A 1.4 million gallon-per-year demonstration-scale facility, currently
under construction, to produce cellulosic ethanol from sugarcane
bagasse and specially-bred energy cane;
-- A diverse and growing portfolio of commercialized industrial enzyme
products; and
-- Over 300 issued or in-licensed patents for its technologies and
processes, as well as over 450 pending patents.
Verenium will be structured and managed as three distinct, but
interdependent, organizational units: Specialty Enzymes Business Unit,
Biofuels Business Unit, and Research and Development. The Specialty Enzymes
Business Unit currently generates commercial revenue from multiple sources,
including industrial enzyme product sales, technology licenses, strategic
partnerships, and government grants. The Biofuels Business Unit will be
primary focused on the commercial-scale production and sale of cellulosic
ethanol from company-managed production facilities throughout the US, as
well as strategic partnerships and related revenue arrangements around the
world. The Research and Development organization's primary goal will be to
support both Verenium Business Units, as well as various existing strategic
collaborative partners. As of March 31, 2007, the Company had cash,
cash-equivalents, and short-term investments on hand of approximately
$125.5 million, which, together with approximately $20 million received in
early April from the exercise of an over-allotment option related to the
recent convertible notes offering, it believes to be sufficient to fund
operations through at least 2008.
Verenium's Board of Directors will initially consist of nine members,
six from Diversa and three from Celunol, including Mr. Riva. The
non-employee Board members are: Dr. James Cavanaugh, who will serve as
Chairman of the Board of Directors; Peter Johnson; Fernand Kaufmann, Ph.D.;
Mark Leschly; Melvin Simon, Ph.D.; Cheryl Wenzinger; Joshua Ruch; and
Michael Zak.
The Company's executive management team is being led by Carlos A. Riva,
President, Chief Executive Officer, and Director, and John A. McCarthy,
Jr., Executive Vice President and Chief Financial Officer.
Verenium will be headquartered in Cambridge, Massachusetts and have
research and operations facilities in San Diego, California; Jennings,
Louisiana; and Gainesville, Florida. Due to the complementary nature of the
two companies and the level of development activities being pursued, the
company anticipates increasing its staff in Cambridge and Jennings, as well
as building additional staff over time in San Diego to support the growth
of the enzyme business and research and development efforts of the Company.
In connection with the merger, Diversa will issue 15 million shares of
common stock in exchange for all outstanding equity securities of Celunol,
which includes shares issuable under Celunol options and warrants that will
be assumed by the Company. As a result of the merger, former Celunol
security holders will own approximately 24 percent of the Company, while
Diversa shareholders will own approximately 76 percent. Immediately
following the merger, the Company will have approximately 63 million shares
outstanding.
About Verenium
Cambridge-based Verenium Corporation is a leader in the development and
commercialization of cellulosic ethanol, an environmentally-friendly and
renewable transportation fuel, as well as high-performance specialty
enzymes for applications within the biofuels, industrial, and health and
nutrition markets. The Company possesses integrated, end-to-end
capabilities in pre- treatment, novel enzyme development, fermentation,
engineering, and project development and is moving rapidly to commercialize
its proprietary technology for the production of ethanol from a wide array
of feedstocks, including sugarcane bagasse, dedicated energy crops,
agricultural waste, and wood products. In addition to the vast potential
for biofuels, a multitude of large-scale industrial opportunities exist for
the Company for products derived from the production of low-cost,
biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to
create a broad range of specialty products to meet high-value commercial
needs. Verenium's world class R&D organization is renowned for its
capabilities in the rapid screening, identification, and expression of
enzymes-proteins that act as the catalysts of biochemical reactions.
Verenium recently completed a significant upgrade of one of the
nation's first operational cellulosic ethanol pilot facilities located in
Jennings, Louisiana and expects to achieve mechanical completion of a 1.4
million gallon-per-year, demonstration-scale facility to produce cellulosic
ethanol by the end of 2007. In addition, the Company's process technology
has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co.,
LTD and has been incorporated into BioEthanol Japan's 1.4 million
liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's
first commercial-scale plant to produce cellulosic ethanol from wood
construction waste. For more information on Verenium, visit
http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include statements related to the Company's competitive advantages and
position, technical, operations, production and personnel capabilities,
commercial opportunities, prospects for technical and commercial
development and success, plans for expanding its cellulosic ethanol
business, including by managing production facilities throughout the U.S.
and through strategic partnerships and other arrangements elsewhere, and
other growth, and the sufficiency of its cash equivalents to fund its
operations through 2008. Such statements are only predictions, and actual
events or results may differ materially from those projected in such
forward-looking statements. Factors that could cause or contribute to
differences include, but are not limited to, the risk that the Company may
not be able to successfully integrate its businesses or achieve synergies
in a timely manner or to the extent anticipated, the risk that the
marketplace for the Company's products and product candidates may change or
be impacted by competition, supply issues or marketplace trends, the risk
that technical, regulatory or manufacturing issues, new data or
intellectual property disputes may affect the Company's commercial and/or
development programs or that the Company may encounter other difficulties
in developing its products, product candidates, and/or processes or in
gaining approval or market acceptance of new products, processes, and/or
technologies and risks and other uncertainties more fully described in the
Company's (formerly Diversa's) filings with the Securities and Exchange
Commission, including, but not limited to, the Company's (formerly
Diversa's) quarterly report on Form 10-Q for the quarter ended March 31,
2007. These forward-looking statements speak only as of the date hereof.
The Company expressly disclaims any intent or obligation to update these
forward-looking statements.
Jo
Wenn ich es richtig verstehe haben sich Diversa Corporation und Celunol Corp. unter dem Namen Verenium zusammengetan.
Wenn ich es richtig verstehe haben sich Diversa Corporation und Celunol Corp. unter dem Namen Verenium zusammengetan.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 104 | ||
| 93 | ||
| 77 | ||
| 47 | ||
| 43 | ||
| 41 | ||
| 40 | ||
| 31 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 29 | ||
| 28 | ||
| 27 | ||
| 25 | ||
| 24 | ||
| 24 | ||
| 24 | ||
| 22 | ||
| 21 | ||
| 19 |
